CoChat

Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil

Open access
Ranzani, Otavio T., Hitchings, Matt D. T., de Melo, Rosana Leite, de França, Giovanny V. A., Fernandes, Cássia de Fátima R., Lind, Margaret L., Torres, Mario Sergio Scaramuzzini, Tsuha, Daniel Henrique, David, Leticia C. S., Said, Rodrigo F. C., Almiron, Maria, de Oliveira, Roberto D., Cummings, Derek A. T., Dean, Natalie E., Andrews, Jason R., Ko, Albert I., Croda, Julio · 2022 · Nature Communications

Published version of a preprint

Cited by 111

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

The effectiveness of inactivated vaccines (VE) against symptomatic and severe COVID-19 caused by omicron is unknown. We conducted a nationwide, test-negative, case-control study to estimate VE for homologous and heterologous (BNT162b2) booster doses in adults who received two doses of CoronaVac in Brazil in the Omicron context. Analyzing 1,386,544 matched-pairs, VE against symptomatic disease was 8.6% (95% CI, 5.6–11.5) and 56.8% (95% CI, 56.3–57.3) in the period 8–59 days after receiving a homologous and heterologous booster, respectively. During the same interval, VE against severe Covid-19 was 73.6% (95% CI, 63.9–80.7) and 86.0% (95% CI, 84.5–87.4) after receiving a homologous and heterologous booster, respectively. Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-022-33169-0

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 21

  1. Ranzani, O. T. et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ. https://doi.org/10.1136/bmj.n2015 (2021). · DOI · Paper page
  2. Cerqueira-Silva, T. et al. Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil. Nat. Med. https://doi.org/10.1038/s41591-022-01701-w (2022). · DOI · Paper page
  3. Andrews, N. et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2119451 (2022). · doi:10.1056/nejmoa2119451 · Paper page
  4. Strategic Advisory Group of Experts on Immunization—SAGE (WHO). Highlights from the Meeting of the Strategic Advisory Group of Experts (SAGE) on Immunization, 4-7 October 2021. (2021).
  5. Dolgin, E. Omicron thwarts some of the world’s most-used COVID vaccines. Nature 601, 311–311 (2022). · DOI
  6. Cheng, S. M. S. et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat. Med 28, 486–489 (2022). · DOI · Paper page
  7. Lu, L. et al. Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients. Clin. Infect. Dis. ciab1041 https://doi.org/10.1093/cid/ciab1041 (2021). · DOI · Paper page
  8. Costa Clemens, S. A. et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet 399, 521–529 (2022). · DOI · Paper page
  9. Zeng, G. et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect. Dis. 22, 483–495 (2022). · DOI · Paper page
  10. Jara, A. et al. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. Lancet Glob. Health 10, e798–e806 (2022). · DOI · Paper page
  11. Hitchings, M. D. T. et al. Change in covid-19 risk over time following vaccination with CoronaVac: test negative case-control study. BMJ e070102 https://doi.org/10.1136/bmj-2022-070102 (2022). · DOI
  12. Kahn, R., Schrag, S. J., Verani, J. R. & Lipsitch, M. Identifying and Alleviating Bias Due to Differential Depletion of Susceptible People in Postmarketing Evaluations of COVID-19 Vaccines. Am. J. Epidemiol. 191, 800–811 (2022). · DOI · Paper page
  13. Bodner, K., Knight, J., Hamilton, M. A. & Mishra, S. Higher contact among vaccinated can be a mechanism for negative vaccine effectiveness. https://doi.org/10.1101/2022.04.25.22274266 (2022). · DOI
  14. Kaslow, D. C. Force of infection: a determinant of vaccine efficacy? npj Vaccines 6, 51 (2021). · DOI
  15. Bastos, L. S. et al. COVID-19 and hospitalizations for SARI in Brazil: a comparison up to the 12th epidemiological week of 2020. Cad. Saúde. Pública 36, e00070120 (2020). · doi:10.1590/0102-311x00070120
  16. Sullivan, S. G., Tchetgen Tchetgen, E. J. & Cowling, B. J. Theoretical Basis of the Test-Negative Study Design for Assessment of Influenza Vaccine Effectiveness. Am. J. Epidemiol. 184, 345–353 (2016). · DOI · Paper page
  17. Andrejko, K. L. et al. Prevention of Coronavirus Disease 2019 (COVID-19) by mRNA-Based Vaccines Within the General Population of California. Clin. Infect. Dis. 74, 1382–1389 (2022). · DOI · Paper page
  18. Chua, H. et al. The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology. Epidemiology 31, 43–64 (2020). · DOI · Paper page
  19. Foppa, I. M. et al. The case test-negative design for studies of the effectiveness of influenza vaccine in inpatient settings. Int. J. Epidemiol. dyw022 https://doi.org/10.1093/ije/dyw022 (2016). · DOI
  20. Thompson, M. G. et al. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N. Engl. J. Med 385, 1355–1371 (2021). · DOI · Paper page
  21. Hitchings, M. D. T. et al. Use of Recently Vaccinated Individuals to Detect Bias in Test-Negative Case–Control Studies of COVID-19 Vaccine Effectiveness. Epidemiology 33, 450–456 (2022). · DOI

Cited by

See all 111

Metadata

Authors
Ranzani, O. T., Hitchings, M. D. T., de Melo, R. L., de França, G. V. A., Fernandes, C. D. F. R., Lind, M. L., Torres, M. S. S., Tsuha, D. H., David, L. C. S., Said, R. F. C., Almiron, M., de Oliveira, R. D., Cummings, D. A. T., Dean, N. E., Andrews, J. R., Ko, A. I., & Croda, J.
Venue
Nature Communications
Published
2022-10-06
Volume
13
Issue
1
Pages
5536-5536
ISSN
2041-1723 (ISSN-L)
OpenAlex
W4302293777
Cited by
111
References
14
FWCI
12.02
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil. https://app.cochat.ai/papers/10.1038/s41467-022-33169-0
The paper
Ranzani, O. T., Hitchings, M. D. T., de Melo, R. L., de França, G. V. A., Fernandes, C. D. F. R., Lind, M. L., Torres, M. S. S., Tsuha, D. H., David, L. C. S., Said, R. F. C., Almiron, M., de Oliveira, R. D., Cummings, D. A. T., Dean, N. E., Andrews, J. R., Ko, A. I., & Croda, J. (2022). Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil. Nature Communications. https://doi.org/10.1038/s41467-022-33169-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.